Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI by Matthew Sims, Charles Berenson, Stuart Cohen, Elaine Wang, Elizabeth Hohmann, Richard Nathan, Alberto Odio, Paul Cook, Kelly Brady, David Lombardi, Asli Memisoglu, Ananya De, Brooke Hasson, Bret Lashner, Louis Korman, Doria Grimard, Juan Carlos Moises Gutierrez, Barbara McGovern, Lisa Von Moltke

Get full text